BrainsWay (BWAY) Q4 2023: 50% Revenue Surge Anchors Breakout Profitability and International Expansion
BrainsWay delivered a standout Q4 with a 50% revenue jump, marking its first profitable quarter and a second consecutive period of positive cash flow. The company’s focus on enterprise accounts, international placements, and recurring revenue is showing visible traction, with management issuing its first-ever annual guidance on the back of this momentum. With new clinical evidence and a robust innovation pipeline, BrainsWay is positioning for durable growth and increased market share in 2024 and beyond.
Summary
- Enterprise Shift Accelerates: Focus on institutional accounts and recurring models is driving margin expansion and install growth.
- International Placements Gain Momentum: Non-US markets, especially Asia and Europe, are fueling system placements and broader clinical adoption.
- Profitability Inflection Point: Transition to positive net income and cash flow signals a step-change in business model leverage.
Business Overview
BrainsWay develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS) systems, which are non-invasive medical devices used for the treatment of neuropsychiatric disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction. The company generates revenue through direct sales, leasing, and recurring service agreements with mental health providers, hospitals, and clinics. Its business is split between US and international markets, with growing emphasis on enterprise customers and pay-per-use models.
Performance Analysis
BrainsWay’s Q4 2023 results marked a major inflection, with revenue up 50% year-over-year, driven by both US and international placements. The company shipped 60 Deep TMS systems in the quarter, lifting its installed base to 1,101 units, a 25% increase from the prior year. Gross margin improved to 75%, reflecting favorable product mix and operational discipline. Operating expenses declined across sales, R&D, and G&A, supporting a swing to operating profit and positive adjusted EBITDA for the second straight quarter.
International growth was a particular highlight, with South Korea’s installed base surpassing 20 systems and Europe showing uptake across a broader set of indications. The OCD treatment add-on continued to gain traction, now present in about half of the installed base. Strong cash discipline was evident, with the company ending the year with $46.3 million in cash and no debt, and positive cash flow from operations for the second consecutive quarter.
- Margin Expansion: Gross margin rose to 75%, supported by operational leverage and mix shift toward higher-value recurring agreements.
- OCD Indication Uptake: 64 OCD coils shipped in Q4, with OCD capability now in about 50% of systems, expanding the company’s addressable market.
- Cash Flow Inflection: Positive operating cash flow for two quarters, underscoring improved financial discipline and business model resilience.
The combination of revenue acceleration, margin gains, and cost control has repositioned BrainsWay as a profitable, cash-generative growth company, setting the stage for continued investment in innovation and commercial expansion.
Executive Commentary
"We significantly exceeded those expectations. Specifically, our revenues grew 17% in 2023 as compared to 2022. Most importantly, we generated positive quarterly net income in the fourth quarter. In Q4, we also recorded positive adjusted EBITDA and cash flow from operations for the second consecutive quarter."
Adar Levy, Chief Executive Officer
"Based on our robust US pipeline and continued momentum internationally for full year 2024, we expect revenue in the range of $37 million to $40 million and anticipate that our profitability momentum and positive cash generation will continue throughout the year."
Ido Marone, Chief Financial Officer
Strategic Positioning
1. Enterprise and Recurring Revenue Focus
BrainsWay is increasingly targeting large institutional and enterprise mental health groups, shifting from transactional sales to recurring revenue models such as leasing and pay-per-use. This transition is improving customer stickiness, expanding margins, and aligning with evolving industry consolidation trends. Management reports that most new demand is oriented toward these recurring service models, which are valued by customers for their flexibility and support.
2. International Expansion and Indication Diversification
International markets, particularly in Asia and Europe, are accelerating as growth drivers. The company’s CE clearances in Europe for 12 indications, including Parkinson’s and stroke rehab, enable broader adoption than in the US. Strategic distributor partnerships and expanding clinical evidence are supporting deeper penetration, with management expecting this momentum to continue in 2024.
3. Clinical Validation and Innovation Pipeline
BrainsWay is investing in clinical studies to broaden its addressable market and reinforce payer support. Recent publications demonstrated Deep TMS efficacy in Parkinson’s and late-life depression, while new feasibility trials for the DeepTMS360 rotational field technology target stroke rehabilitation and accelerated OCD protocols. These initiatives aim to position BrainsWay as a leader in TMS innovation and to unlock new high-value indications.
4. Reimbursement Tailwinds
Favorable reimbursement trends are reducing patient eligibility barriers, with major insurers lowering requirements for TMS coverage. This is expanding the pool of treatable patients, particularly in the US, and supporting sustained demand for BrainsWay’s systems and services.
5. Balance Sheet Strength
The company’s $46.3 million cash balance and zero debt provide ample flexibility for continued investment in R&D, commercial expansion, and potential strategic partnerships, supporting its growth ambitions without near-term capital risk.
Key Considerations
This quarter’s results reflect a clear operational and strategic turning point, with BrainsWay now demonstrating both growth and profitability. Investors should weigh the durability of these trends against the evolving competitive and regulatory landscape.
Key Considerations:
- Recurring Business Model Maturity: The shift to leasing and service models is enhancing revenue visibility but requires ongoing investment in customer success and support infrastructure.
- Indication Expansion Potential: Clinical validation for new uses like Parkinson’s and stroke rehab could unlock sizable incremental markets, but regulatory approvals and payer adoption will be critical gating factors.
- International Execution Risk: Growth in Asia and Europe is promising, yet depends on distributor performance, local reimbursement, and regulatory environments.
- Innovation Pipeline Impact: The success of DeepTMS360 and accelerated protocols could be a catalyst for market expansion and competitive differentiation, but clinical and commercial risks remain.
Risks
BrainsWay faces competitive pressure from other TMS and neurostimulation device makers, as well as from alternative therapies such as ketamine clinics. Regulatory hurdles and payer coverage for new indications remain uncertain. International expansion introduces distributor, reimbursement, and geopolitical risks. Management’s new guidance and profitability targets raise the bar for execution, and any slowdown in enterprise demand or reimbursement setbacks could pressure results.
Forward Outlook
For Q1 2024, BrainsWay guided to:
- Continued revenue growth, building on the Q4 momentum
- Ongoing positive cash generation and profitability at the operating and net income lines
For full-year 2024, management provided its first annual revenue guidance:
- Revenue expected in the range of $37 million to $40 million, representing 16% to 26% growth over 2023
Management highlighted several factors that support its outlook:
- Robust US and international pipelines, with enterprise and institutional demand leading
- Favorable reimbursement trends and new clinical evidence supporting broader adoption
Takeaways
BrainsWay’s Q4 results signal a structural shift to profitable, cash-generative growth. The business model transition toward enterprise and recurring revenue, coupled with strong international momentum and an expanding innovation pipeline, position the company for continued outperformance.
- Profitability Inflection: Q4 marks a turning point, with positive net income and cash flow validating the recurring model and operational discipline.
- Strategic Clinical Expansion: New data in Parkinson’s and late-life depression, along with DeepTMS360 trials, could drive future indication growth and market share gains.
- Pipeline and Execution Watch: Investors should monitor the pace of international placements, enterprise adoption, and clinical readouts as key drivers for 2024 and beyond.
Conclusion
BrainsWay’s Q4 2023 performance reflects a decisive operational and financial inflection. The company’s expansion into enterprise accounts, international markets, and new clinical indications underpins its growth trajectory, while profitability and cash flow momentum de-risk the path forward. Execution on innovation and commercial expansion will determine the sustainability of these gains.
Industry Read-Through
BrainsWay’s results highlight several sector-wide forces: The shift toward recurring revenue and enterprise accounts is becoming standard in medical device commercial models, while clinical validation and payer acceptance remain key to unlocking new indications. International diversification is increasingly important for device makers facing saturated US markets. Competitors in neurostimulation, mental health, and adjacent therapeutic device categories should expect rising customer expectations for service, flexibility, and evidence-backed expansion. The success of accelerated treatment protocols and new clinical applications could catalyze broader adoption of non-invasive neuromodulation technologies.